RxDoctor Payments Data

Timothy Hormel, MD

Neurology · Salem, VANPI 1972577997

Payments from drug & device makers

$55,233in general payments, 2019–2025

Across 442 payments — averaging $124.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$32K
  • AbbVie$16K
  • Biohaven Pharmaceuticals, Inc.$2K
  • Biogen$570
  • Novartis$367
  • Avanir Pharmaceuticals, Inc.$301
  • plus $4K from 40 others

What the payments were for

  • Consulting fees$1,3002%
  • Speaking & faculty fees$44,65881%
  • Travel & lodging$1,7763%
  • Food & beverage$7,37413%
  • Education$1260%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,233 in reported general payments places this provider in the 85th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$55,766
Medicare patients
340
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone16$231,820
GilenyaFingolimod Hcl11$120,460
CopaxoneGlatiramer Acetate13$74,600
Nurtec OdtRimegepant Sulfate40$73,819
Aimovig AutoinjectorErenumab-Aooe24$49,209
KeppraLevetiracetam13$37,735
VimpatLacosamide20$31,974
QuliptaAtogepant25$27,061
BriviactBrivaracetam21$25,073
Emgality PenGalcanezumab-Gnlm12$16,405
Rasagiline Mesylate29$10,737
Carbidopa-LevodopaCarbidopa/Levodopa173$8,263
DilantinPhenytoin Sodium Extended25$8,221
Carbidopa-Levodopa ErCarbidopa/Levodopa86$7,613
Lacosamide42$6,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisGilenya$367$120,46011 claims
PfizerNurtec Odt, Dilantin$54$82,03965 claims
Teva Pharmaceuticals USA, Inc.Copaxone$31,610$74,60013 claims
UCB, Inc.Vimpat, Briviact$120$57,04741 claims
AbbVieQulipta$16,336$27,06125 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$193$6,26038 claims
Upsher-smith Laboratories LLCTopiramate$176$53142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 neurology providers in Virginia.

Other neurology in Salem

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →